

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	August 27, 2024

**Toujeo® SoloStar/Max SoloStar (insulin glargine)**

**LENGTH OF AUTHORIZATION:** One year

**REVIEW CRITERIA:**

- Patient must be ≥ 6 years of age; **AND**
- Patient must have a diagnosis of diabetes mellitus; **AND**
- Patient had an inadequate response or intolerance to no less than a 6-month trial on Lantus® (insulin glargine) demonstrated by, but not limited to the following - *clinical documentation (e.g., progress notes, lab results, etc.) detailing treatment response must be provided:*
  - Recurrent episodes of hypoglycemia despite adjustments to dose/dosage frequency.
  - **For Toujeo Max SoloStar** – failure to achieve glycemic control goals on Lantus® (insulin glargine) **AND** high dose insulin glargine therapy is medically necessary.

Note: Toujeo is not recommended for the treatment of diabetic ketoacidosis.

**CONTINUATION OF THERAPY:**

- Patient met initial review criteria; **AND**
- Documentation of improved clinical response (e.g., reduction in hypoglycemic episodes, HbA1c, and fasting blood glucose); **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia.

**DOSING AND ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 300 units/mL (U-300) insulin glargine for injection:
  - 1.5 mL SoloStar single-use prefilled pen
  - 3 mL Max SoloStar single-use prefilled pen